Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sirnaomics Names China Partner for siRNA Therapeutic

publication date: Jun 23, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sirnaomics, located in Maryland, USA, has partnered with Guangdong Zhongsheng Pharmaceutical Co. to develop its small interfering RNA (siRNA) ocular neovascularization therapeutic. The partnership will seek to develop and commercialize STP601, a Sirnaomics siRNA candidate for treatment of diabetic retinopathy and age-related macular degeneration. Zhongsheng Pharma is committing 63 million RMB ($9.8 million) to the partnership, including upfront and milestone payments. More details....

Stock Symbol: (SZE: 002317)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors